Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-20
DOI
10.1038/s41467-020-15726-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.
- (2019) Sushma Jonna et al. JOURNAL OF CLINICAL ONCOLOGY
- Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
- (2019) Ines Pires da Silva et al. CANCER
- IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma
- (2019) Jason A. Carter et al. NATURE MEDICINE
- Reply to: ‘IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma’
- (2019) Noam Auslander et al. NATURE MEDICINE
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
- (2018) Natalie J. Neubert et al. Science Translational Medicine
- Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
- (2018) Arnav Mehta et al. Cancer Discovery
- Complex pattern of immune evasion in MSI colorectal cancer
- (2018) Mine Ozcan et al. OncoImmunology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
- (2017) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma
- (2017) Jenny H. J. Lee et al. Pigment Cell & Melanoma Research
- Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
- (2017) Antje Sucker et al. Nature Communications
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
- (2017) Alexandre Reuben et al. Cancer Discovery
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- Reprogramming the immunological microenvironment through radiation and targeting Axl
- (2016) Todd A. Aguilera et al. Nature Communications
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia
- (2015) R H Rouce et al. LEUKEMIA
- TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells
- (2015) Xiao-Hui Chen et al. MOLECULAR IMMUNOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization
- (2015) Yaiza del Pozo Martin et al. Cell Reports
- BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
- (2015) S. D. Bradley et al. Cancer Immunology Research
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
- (2015) D. S. Thommen et al. Cancer Immunology Research
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- voom: precision weights unlock linear model analysis tools for RNA-seq read counts
- (2014) Charity W Law et al. GENOME BIOLOGY
- Systematic evaluation of spliced alignment programs for RNA-seq data
- (2013) Pär G Engström et al. NATURE METHODS
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase
- (2011) Marialuisa Sensi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
- (2009) Sebastian Haferkamp et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started